Alpharetroviral self-inactivating vectors produced by a superinfection-resistant stable packaging cell line allow genetic modification of primary human T lymphocytes

Biomaterials

Volumn 97, Issue , 2016, Pages 97-109

  Labenski, Verena ^a   Suerth, Julia D ^a   Barczak, Elke ^a   Heckl, Dirk ^a,b   Levy, Camille ^c   Bernadin, Ornellie ^c   Charpentier, Emmanuelle ^b   Williams, David A ^d,e,f   Fehse, Boris ^g   Verhoeyen, Els ^c,h   Schambach, Axel ^a,d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITÉ LYON 1   (France)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

Alpharetroviral SIN vector; CRISPR Cas9; Immunotherapy; Stable packaging cell line; Superinfection; TK007

Indexed keywords

CELL CULTURE; CELL MEMBRANES; CELL PROLIFERATION; CELLS; COST EFFECTIVENESS; COST ENGINEERING; GENES; LYMPHOCYTES; PACKAGING; PRODUCTION PLATFORMS; T-CELLS; VECTORS; VIRUSES;

CRISPR-CAS9; IMMUNOTHERAPY; PACKAGING CELL LINE; SUPERINFECTION; TK007;

CYTOLOGY;

ALPHARETROVIRAL SELF INACTIVATING VECTOR; EXCITATORY AMINO ACID TRANSPORTER; GANCICLOVIR; RETROVIRUS VECTOR; SLC1A5 PROTEIN; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADULT; ALPHAROMEO CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENGINEERING; CONTROLLED STUDY; CRISPR CAS SYSTEM; DRUG EFFICACY; EMBRYO; GENETIC TRANSDUCTION; GENOME; HEK293 CELL LINE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; IN VITRO STUDY; IN VIVO GENE TRANSFER; INFECTION PREVENTION; JURKAT CELL LINE; MOUSE; MYELOPROLIFERATIVE SARCOMA VIRUS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SARCOMA VIRUS; STABLE EXPRESSION; SUICIDE GENE THERAPY; SUICIDE TRANSGENE; SUPERINFECTION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; ALPHARETROVIRUS; CELL CLONE; GENE VECTOR; GENETIC PROCEDURES; GENETICS; IMMUNOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; REPORTER GENE; REPRODUCIBILITY; TRANSGENE; VIRUS ASSEMBLY;

ALPHARETROVIRUS; BASE SEQUENCE; CLONE CELLS; CRISPR-CAS SYSTEMS; GENES, REPORTER; GENETIC TECHNIQUES; GENETIC VECTORS; HEK293 CELLS; HUMANS; JURKAT CELLS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSGENES; VIRUS ASSEMBLY;

EID: 84964955852     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.04.019     Document Type: Article

References (62)

1. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8(4):299-308.
2. Ramos C.A., Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin. Biol. Ther. 2011, 11(7):855-873.
3. June C.H., Maus M.V., Plesa G., et al. Engineered T cells for cancer therapy. Cancer Immunol. Immunother. 2014, 63(9):969-975.
4. Duong C.P.M., Yong C.S.M., Kershaw M.H., Slaney C.Y., Darcy P.K. Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic. Mol. Immunol. 2015, 67(2 Pt A):46-57.
5. Cieri N., Mastaglio S., Oliveira G., et al. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol. Rev. 2014, 257(1):165-180.
6. Baker K.S., Fraser C.J. Quality of life and recovery after graft-versus-host disease. Best Pract. Res. Clin. Haematol. 2008, 21(2):333-341.
7. Preuss E., Treschow A., Newrzela S., et al. TK.007: a novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy. Hum. Gene Ther. 2010, 21(8):929-941.
8. Preuss E., Muik A., Weber K., et al. Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J. Mol. Med. (Berl). 2011, 89(11):1113-1124.
9. Montini E., Cesana D., Schmidt M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Investig. 2009, 119(4):964-975.
10. Cesana D., Sgualdino J., Rudilosso L., et al. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J. Clin. Investig. 2012, 122(5):1667-1676.
11. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302(5644):415-419.
12. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Investig. 2008, 118(9):3132-3142.
13. Howe S.J., Mansour M.R., Schwarzwaelder K., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 2008, 118(9):3143-3150.
14. Stein S., Ott M.G., Schultze-Strasser S., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010, 16(2):198-204.
15. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467(7313):318-322.
16. Recchia A., Bonini C., Magnani Z., et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(5):1457-1462.
17. Scholler J., Brady T.L., Binder-Scholl G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 2012, 4(132):132ra53.
18. Dunbar C.E., Hu J.Q., Ferris A., et al. Transduction of rhesus macaque hematopoietic stem and progenitor cells with avian sarcoma and leukosis viral vectors. Hum. Gene Ther. 2007, 18(8):691-700.
19. Hu J., Renaud G., Gomes T.J., et al. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol. Ther. 2008, 16(9):1617-1623.
20. Suerth J.D., Maetzig T., Brugman M.H., et al. Alpharetroviral self-inactivating vectors: long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol. Ther. 2012, 20(5):1022-1032.
21. Kaufmann K.B., Brendel C., Suerth J.D., et al. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing. Mol. Ther. 2013, 21(3):648-661.
22. Moiani A., Suerth J.D., Gandolfi F., et al. Genome-wide analysis of alpharetroviral integration in human hematopoietic stem/progenitor cells. Genes (Basel). 2014, 5(2):415-429.
23. Suerth J.D., Maetzig T., Galla M., Baum C., Schambach A. Self-inactivating alpharetroviral vectors with a split-packaging design. J. Virol. 2010, 84(13):6626-6635.
24. Merten O.-W. State-of-the-art of the production of retroviral vectors. J. Gene Med. 2004, 6(Suppl. 1):S105-S124.
25. Coroadinha A.S., Gama-Norton L., Amaral A.I., et al. Production of retroviral vectors: review. Curr. Gene Ther. 2010, 10:456-473.
26. Loew R., Meyer Y., Kuehlcke K., et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther. 2010, 17(2):272-280.
27. Sheridan P.L., Bodner M., Lynn A., et al. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer. Mol. Ther. 2000, 2(3):262-275.
28. Ghani K., Cottin S., Kamen A., Caruso M. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther. 2007, 14(24):1705-1711.
29. Schucht R., Coroadinha A.S., Zanta-Boussif M.A., et al. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol. Ther. 2006, 14(2):285-292.
30. Kaplan A.H., Swanstrom R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(10):4528-4532.
31. Ni Y., Sun S., Oparaocha I., et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 2005, 7(6):818-834.
32. Klages N., Zufferey R., Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther. 2000, 2(2):170-176.
33. Ikeda Y., Takeuchi Y., Martin F., et al. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 2003, 21(5):569-572.
34. Broussau S., Jabbour N., Lachapelle G., et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther. 2008, 16(3):500-507.
35. Vogt B., Roscher S., Abel B., et al. Lack of superinfection interference in retroviral vector producer cells. Hum. Gene Ther. 2001, 12(4):359-365.
36. Brandtner E.M., Kodajova P., Knapp E., et al. Quantification and characterization of autotransduction in retroviral vector producer cells. Hum. Gene Ther. 2008, 19(1):97-102.
37. Stewart H.J., Fong-Wong L., Strickland I., et al. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Hum. Gene Ther. 2011, 22(3):357-369.
38. Hennig K., Raasch L., Kolbe C., et al. HEK293-based production platform for γ-retroviral (SIN-) vectors: application for safe and efficient transfer of COL7A1 cDNA. Hum. Gene Ther. Clin. Dev. 2014, 25(4):218-228.
39. Chong H., Starkey W., Vile R.G. A Replication-competent Retrovirus Arising from a Split-function Packaging Cell Line Was Generated by Recombination Events between the Vector, One of the Packaging Constructs, and Endogenous Retroviral Sequences a Replication-competent Retrovirus Arisin 1998.
40. Kim Y.S., Lim H.K., Kim K.J. . Production of high-titer retroviral vectors and detection of replication-competent retroviruses. Mol. Cells 1998, 8(1):36-42.
41. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antivir. Res. 2006, 71(2-3):154-163.
42. Yang Y., Vanin E.F., Whitt M.A., et al. Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum. Gene Ther. 1995, 6(9):1203-1213.
43. Beyer W.R., Westphal M., Ostertag W., von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J. Virol. 2002, 76(3):1488-1495.
44. Sandrin V., Boson B., Salmon P., et al. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100(3):823-832.
45. Fehse B., Kustikova O.S., Bubenheim M., Baum C. Pois(s)on-it's a question of dose. Gene Ther. 2004, 11(11):879-881.
46. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36(1):59-74.
47. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29(9):e45.
48. Hsu P.D., Scott D a, Weinstein J a, et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 2013, 31(9):827-832.
49. Heckl D., Kowalczyk M.S., Yudovich D., et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 2014, 32(9):941-946.
50. Engels B., Cam H., Schüler T., et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 2003, 14(12):1155-1168.
51. Xue S.-A., Gao L., Thomas S., et al. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 2010, 95(1):126-134.
52. Di Stasi A., Tey S.-K., Dotti G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365(18):1673-1683.
53. Rasko J.E.J., Battini J.L., Gottschalk R.J., Mazo I., Miller A.D. The RD114 simian type D retrovirus receptor is a neutral amino acid transporter. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(5):2129-2134.
54. Coffin J.M., Hughes S.H., Varmus H.E. Retroviruses 1997.
55. Jobbagy Z., Garfield S., Baptiste L., Eiden M.V., Anderson W.B. Subcellular redistribution of Pit-2 Pi transporter/amphotropic leukemia virus (A-MuLV) receptor in A-MuLV-infected NIH 3T3 fibroblasts: involvement in superinfection interference. J. Virol. 2000, 74(6):2847-2854.
56. Spitzer D., Dittmar K.E.J., Rohde M., Hauser H., Wirth D. Green fluorescent protein-tagged retroviral envelope protein for analysis of virus-cell interactions. J. Virol. 2003, 77(10):6070-6075.
57. Marin M., Tailor C.S., Nouri A., Kabat D. Sodium-dependent neutral amino acid transporter type 1 is an auxiliary receptor for baboon endogenous retrovirus. J. Virol. 2000, 74(17):8085-8093.
58. Girard-Gagnepain A., Amirache F., Costa C., et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 2014, 124(8):1221-1231.
59. Ciceri F., Bonini C., Stanghellini M.T.L., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet. Oncol. 2009, 10(5):489-500.
60. Frecha C., Szécsi J., Cosset F.-L., Verhoeyen E. Strategies for targeting lentiviral vectors. Curr. Gene Ther. 2008, 8(6):449-460.
61. Cosset F.-L., Takeuchi Y., Battini J.-L., Weiss R.A., Collins M.K.L. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 1995, 69(12):7430-7436.
62. Yee J.K., Friedmann T., Burns J.C. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol. 1994, 43(Pt A):99-112.